# TaoWeave, Inc.: financial statements, quarterly

TWAV · Nasdaq · CIK 746210 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/twav.md) · [Financials](/companies/twav/financials.md) · [Filings](/companies/twav/filings.md) · [Insiders](/companies/twav/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/twav/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [872](/filings/0001437749-24-033771.md) | [944 d](/filings/0001437749-25-008262.md) | [626](/filings/0001437749-25-016275.md) | [611](/filings/0001437749-25-026680.md) | [578](/filings/0001437749-25-034612.md) | [563 d](/filings/0001437749-26-009237.md) | [622](/filings/0001437749-26-017382.md) | [592](/filings/0001437749-26-026577.md) | [601](/filings/0001437749-25-034612.md) | [622 d](/filings/0001437749-26-009237.md) | [707](/filings/0001437749-26-017382.md) | [522](/filings/0001437749-26-026577.md) |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | [224](/filings/0001437749-24-033771.md) | [289 d](/filings/0001437749-25-008262.md) | [(3.0)](/filings/0001437749-25-016275.md) | [120](/filings/0001437749-25-026680.md) | [79.0](/filings/0001437749-25-034612.md) | [135 d](/filings/0001437749-26-009237.md) | [249](/filings/0001437749-26-017382.md) | [228](/filings/0001437749-26-026577.md) | [244](/filings/0001437749-25-034612.md) | [294 d](/filings/0001437749-26-009237.md) | [470](/filings/0001437749-26-017382.md) | [274](/filings/0001437749-26-026577.md) |
| Research and development | $k | [5.0](/filings/0001437749-24-033771.md) | [4.0 d](/filings/0001437749-25-008262.md) | [50.0](/filings/0001437749-25-016275.md) | [65.0](/filings/0001437749-25-026680.md) | [38.0](/filings/0001437749-25-034612.md) | [2.0 d](/filings/0001437749-26-009237.md) | [3.0](/filings/0001437749-26-017382.md) | [3.0](/filings/0001437749-26-026577.md) | [3.0](/filings/0001437749-25-034612.md) | [2.0 d](/filings/0001437749-26-009237.md) | [0.0](/filings/0001437749-26-017382.md) | [0.0](/filings/0001437749-26-026577.md) |
| Operating income | $k | [(925)](/filings/0001437749-24-033771.md) | [(1,276) d](/filings/0001437749-25-008262.md) | [(1,184)](/filings/0001437749-25-016275.md) | [(1,018)](/filings/0001437749-25-026680.md) | [(1,072)](/filings/0001437749-25-034612.md) | [(928) d](/filings/0001437749-26-009237.md) | [(691)](/filings/0001437749-26-017382.md) | [(683)](/filings/0001437749-26-026577.md) | [(802)](/filings/0001437749-25-034612.md) | [(785) d](/filings/0001437749-26-009237.md) | [(559)](/filings/0001437749-26-017382.md) | [(841)](/filings/0001437749-26-026577.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [0.0](/filings/0001437749-24-033771.md) | [(11.0) d](/filings/0001437749-25-008262.md) | [0.0](/filings/0001437749-25-016275.md) | [9.0](/filings/0001437749-25-026680.md) | [0.0](/filings/0001437749-25-034612.md) | [1.0 d](/filings/0001437749-26-009237.md) | [7.0](/filings/0001437749-26-017382.md) | [0.0](/filings/0001437749-26-026577.md) | [0.0](/filings/0001437749-25-034612.md) | [(5.0) d](/filings/0001437749-26-009237.md) | [0.0](/filings/0001437749-26-017382.md) | [1.0](/filings/0001437749-26-026577.md) |
| Net income | $k | [(895)](/filings/0001437749-24-033771.md) | [(1,221) d](/filings/0001437749-25-008262.md) | [(1,136)](/filings/0001437749-25-034612.md) | [(983)](/filings/0001437749-25-034612.md) | [(1,040)](/filings/0001437749-25-034612.md) | [(884) d](/filings/0001437749-26-009237.md) | [(672)](/filings/0001437749-26-026577.md) | [(605)](/filings/0001437749-26-026577.md) | [(2,290)](/filings/0001437749-25-034612.md) | [(2,788) d](/filings/0001437749-26-009237.md) | [1,697](/filings/0001437749-26-026577.md) | [(3,290)](/filings/0001437749-26-026577.md) |
| Diluted EPS | $ per share | [(0.30)](/filings/0000746210-23-000113.md) | not reported | [(0.07)](/filings/0000746210-24-000019.md) | not reported | not reported | not reported | [(0.59)](/filings/0001437749-26-017382.md) | not reported | not reported | not reported | [0.43](/filings/0001437749-26-017382.md) | not reported |
| Basic EPS | $ per share | [(4.22)](/filings/0001437749-24-033771.md) | not reported | [(2.02)](/filings/0001437749-25-016275.md) | [(1.38)](/filings/0001437749-25-026680.md) | [(11.25)](/filings/0001437749-25-034612.md) | not reported | [(0.59)](/filings/0001437749-26-017382.md) | [(0.38)](/filings/0001437749-26-026577.md) | [(0.74)](/filings/0001437749-25-034612.md) | not reported | [0.43](/filings/0001437749-26-017382.md) | [(0.84)](/filings/0001437749-26-026577.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: not reported
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [6.3](/filings/0001437749-24-033771.md) | [6.0](/filings/0001437749-25-008262.md) | [4.9](/filings/0001437749-25-016275.md) | [5.9](/filings/0001437749-24-025172.md) | [5.6](/filings/0001437749-24-033771.md) | [5.0](/filings/0001437749-26-009237.md) | [4.3](/filings/0001437749-25-016275.md) | [10.8](/filings/0001437749-25-026680.md) | [3.7](/filings/0001437749-25-034612.md) | [2.3](/filings/0001437749-26-026577.md) | [2.1](/filings/0001437749-26-017382.md) | [0.7](/filings/0001437749-26-026577.md) |
| Current assets | $m | [7.6](/filings/0000746210-23-000113.md) | [6.9](/filings/0001437749-25-008262.md) | [5.9](/filings/0000746210-24-000019.md) | [6.3](/filings/0001437749-24-025172.md) | [6.0](/filings/0001437749-24-033771.md) | [5.3](/filings/0001437749-26-009237.md) | [4.8](/filings/0001437749-25-016275.md) | [13.1](/filings/0001437749-25-026680.md) | [10.9](/filings/0001437749-25-034612.md) | [8.2](/filings/0001437749-26-026577.md) | [10.0](/filings/0001437749-26-017382.md) | [5.7](/filings/0001437749-26-026577.md) |
| Total assets | $m | [8.0](/filings/0000746210-23-000113.md) | [6.9](/filings/0001437749-25-008262.md) | [5.9](/filings/0000746210-24-000019.md) | [6.3](/filings/0001437749-24-025172.md) | [6.0](/filings/0001437749-24-033771.md) | [5.3](/filings/0001437749-26-009237.md) | [4.8](/filings/0001437749-25-016275.md) | [13.1](/filings/0001437749-25-026680.md) | [10.9](/filings/0001437749-25-034612.md) | [8.2](/filings/0001437749-26-026577.md) | [10.0](/filings/0001437749-26-017382.md) | [6.8](/filings/0001437749-26-026577.md) |
| Current liabilities | $m | [1.3](/filings/0000746210-23-000113.md) | [1.4](/filings/0001437749-25-008262.md) | [1.5](/filings/0000746210-24-000019.md) | [1.2](/filings/0001437749-24-025172.md) | [1.3](/filings/0001437749-24-033771.md) | [1.3](/filings/0001437749-26-009237.md) | [1.4](/filings/0001437749-25-016275.md) | [1.8](/filings/0001437749-25-026680.md) | [1.1](/filings/0001437749-25-034612.md) | [1.2](/filings/0001437749-26-026577.md) | [1.3](/filings/0001437749-26-017382.md) | [1.3](/filings/0001437749-26-026577.md) |
| Total liabilities | $m | [1.3](/filings/0000746210-23-000113.md) | [1.4](/filings/0001437749-25-008262.md) | [1.5](/filings/0000746210-24-000019.md) | [1.3](/filings/0001437749-24-025172.md) | [1.3](/filings/0001437749-24-033771.md) | [1.3](/filings/0001437749-26-009237.md) | [1.4](/filings/0001437749-25-016275.md) | [1.8](/filings/0001437749-25-026680.md) | [1.1](/filings/0001437749-25-034612.md) | [1.2](/filings/0001437749-26-026577.md) | [1.3](/filings/0001437749-26-017382.md) | [1.3](/filings/0001437749-26-026577.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.7](/filings/0001437749-24-033771.md) | [5.5](/filings/0001437749-26-009237.md) | [4.4](/filings/0001437749-25-034612.md) | [5.1](/filings/0001437749-25-034612.md) | [4.7](/filings/0001437749-25-034612.md) | [4.0](/filings/0001437749-26-026577.md) | [3.4](/filings/0001437749-26-026577.md) | [11.3](/filings/0001437749-26-026577.md) | [9.8](/filings/0001437749-25-034612.md) | [7.0](/filings/0001437749-26-026577.md) | [8.7](/filings/0001437749-26-026577.md) | [5.5](/filings/0001437749-26-026577.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(106) d](/filings/0001437749-24-033771.md) | [(705) d](/filings/0001437749-25-008262.md) | [(630)](/filings/0001437749-25-016275.md) | [(980) d](/filings/0001437749-25-026680.md) | [(911) d](/filings/0001437749-25-034612.md) | [(885) d](/filings/0001437749-26-009237.md) | [(680)](/filings/0001437749-26-017382.md) | [(37.0) d](/filings/0001437749-26-026577.md) | [(1,554) d](/filings/0001437749-25-034612.md) | [(744) d](/filings/0001437749-26-009237.md) | [(650)](/filings/0001437749-26-017382.md) | [(539) d](/filings/0001437749-26-026577.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000746210-23-000113.md) | [0.0 d](/filings/0000746210-24-000009.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2021 (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [17.8](/filings/0000746210-22-000031.md) | [26.6](/filings/0000746210-22-000039.md) | [30.7](/filings/0000746210-22-000047.md) | [2.1](/filings/0000746210-23-000040.md) | [2.1](/filings/0000746210-23-000070.md) | [2.1](/filings/0000746210-23-000113.md) | [2.1](/filings/0000746210-24-000019.md) | [2.5](/filings/0000746210-23-000070.md) | [3.5](/filings/0000746210-23-000113.md) | [17.1](/filings/0000746210-24-000019.md) | [1.2](/filings/0001437749-26-017382.md) | [3.9](/filings/0001437749-26-017382.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 3,877,219 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001437749-26-026577.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.